Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07222410 · ClinicalTrials.gov registry record · NA

Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

A NA study of COPD, sponsored by Fisher and Paykel Healthcare.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT07222410: Recruiting NA study of COPD, sponsored by Fisher and Paykel Healthcare.

NCT07222410 is a NA study of COPD that is actively recruiting participants, run by Fisher and Paykel Healthcare. The registered enrollment target is 70 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07222410, a NA study of COPD, is actively recruiting participants, sponsored by Fisher and Paykel Healthcare.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.

Conditions Studied

Interventions

  • DEVICE Closed loop oxygen control
  • DEVICE Manual titration

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2026-01-07
Est. Completion 2027-11
Phase NA
Fisher and Paykel Healthcare

25 total trials

What NCT07222410 shows while recruiting

NCT07222410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (97% lower).

The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions - of which Closed loop oxygen control is the first listed.

NCT07222410 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT07222410 about?

NCT07222410 is a clinical study titled "Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital". The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.

What is the current status of trial NCT07222410?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2026-01-07. Estimated completion is 2027-11.

What conditions does trial NCT07222410 study?

This clinical trial studies the following conditions: COPD.

What interventions are being tested in trial NCT07222410?

The interventions under investigation include: Closed loop oxygen control (DEVICE), Manual titration (DEVICE).

Who is sponsoring clinical trial NCT07222410?

This trial is sponsored by Fisher and Paykel Healthcare, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07222410 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COPD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07222410's enrollment target sits among peer trials

70 46th of 85 higher than 40 of 85 other COPD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COPD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07222410, the US trial registry maintained by the National Library of Medicine. NCT07222410 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.